Oncocross announced on the 30th through a public disclosure that it has signed a proteomics analysis service contract with OmicsAI to advance its Digital Bio-Banking (DBB) business and build AI-based medical data assets.

OmicsAI will be responsible for sample preprocessing, mass spectrometry-based protein identification and quantification, data interpretation and statistical analysis, and the provision of result reports and raw data.

• ■ Contract Overview
• Contract Period: July 1, 2026 – December 31, 2026
• Contract Scale: 10% or more of 2025 revenue (KRW 3,700,465,89) and 10% or more of equity capital as of the end of 2025 (KRW 13,372,292,787)
• Payment Terms: 50% down payment (July 31, 2026), 25% interim payment (October 30, 2026), 25% final payment (December 31, 2026)

The contract amount and specific terms remain undisclosed for management and business confidentiality reasons. However, the company stated that the contract corresponds to a scale of 10% or more of both its 2025 revenue and equity capital.

■ Data Utilization Direction Oncocross plans to use the proteomics data secured through this contract as key material for strengthening the foundation of its Digital Bio-Banking business and building AI medical data assets. Based on this, the company expects to secure competitiveness in multi-omics data integrating clinical, genomic, and proteomic data, which will contribute to AI-based biomarker discovery, new drug development research, and data-driven business expansion.

■ Other Details The contract amount was calculated based on the scheduled analysis volume and may fluctuate depending on the actual number of analyses completed. It will be settled after the submission of the final report and completion of inspection. The company stated that it will withhold disclosure of detailed contract terms until July 29, 2036.